RU2020115068A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020115068A3 RU2020115068A3 RU2020115068A RU2020115068A RU2020115068A3 RU 2020115068 A3 RU2020115068 A3 RU 2020115068A3 RU 2020115068 A RU2020115068 A RU 2020115068A RU 2020115068 A RU2020115068 A RU 2020115068A RU 2020115068 A3 RU2020115068 A3 RU 2020115068A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/08—Copper compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015062306 | 2015-03-25 | ||
JP2015-062306 | 2015-03-25 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017133107A Division RU2720989C2 (ru) | 2015-03-25 | 2016-03-25 | Способ получения нового азотсодержащего соединения или его соли и получение его промежуточного соединения |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2022103302A Division RU2022103302A (ru) | 2015-03-25 | 2022-02-10 | Способ получения нового азотсодержащего соединения или его соли и получение его промежуточного соединения |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2020115068A RU2020115068A (ru) | 2020-06-26 |
RU2020115068A3 true RU2020115068A3 (ru) | 2020-08-17 |
RU2767398C2 RU2767398C2 (ru) | 2022-03-17 |
Family
ID=56977546
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017133107A RU2720989C2 (ru) | 2015-03-25 | 2016-03-25 | Способ получения нового азотсодержащего соединения или его соли и получение его промежуточного соединения |
RU2020115068A RU2767398C2 (ru) | 2015-03-25 | 2016-03-25 | Применение комплекса азотсодержащего соединения с металлом для диагностики или лечения опухолей с экспрессией интегрина |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017133107A RU2720989C2 (ru) | 2015-03-25 | 2016-03-25 | Способ получения нового азотсодержащего соединения или его соли и получение его промежуточного соединения |
Country Status (24)
Country | Link |
---|---|
US (3) | US20180008583A1 (ru) |
EP (3) | EP4059936A1 (ru) |
JP (1) | JP6411634B2 (ru) |
KR (1) | KR102029746B1 (ru) |
CN (2) | CN107428755B (ru) |
AU (4) | AU2016237099C1 (ru) |
BR (1) | BR112017020484B1 (ru) |
CA (1) | CA2980268C (ru) |
CO (1) | CO2017010806A2 (ru) |
CY (1) | CY1124387T1 (ru) |
DK (1) | DK3275883T3 (ru) |
ES (1) | ES2877707T3 (ru) |
HR (1) | HRP20211031T1 (ru) |
HU (1) | HUE059670T2 (ru) |
IL (4) | IL254532B (ru) |
LT (1) | LT3275883T (ru) |
MX (3) | MX2017012184A (ru) |
PL (1) | PL3275883T3 (ru) |
PT (1) | PT3275883T (ru) |
RS (1) | RS62165B1 (ru) |
RU (2) | RU2720989C2 (ru) |
SG (2) | SG11201707899SA (ru) |
SI (1) | SI3275883T1 (ru) |
WO (1) | WO2016153054A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6215335B2 (ja) | 2013-09-24 | 2017-10-18 | 富士フイルム株式会社 | 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体 |
EP4159727A1 (en) | 2017-02-28 | 2023-04-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
PE20211640A1 (es) | 2018-08-29 | 2021-08-24 | Morphic Therapeutic Inc | INHIBICION DE LA INTEGRINA xvß6 |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
JP2022523947A (ja) * | 2019-03-11 | 2022-04-27 | バイオコンパティブルズ ユーケー リミテッド | 中枢神経系腫瘍の治療方法 |
GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
WO2022136317A1 (en) | 2020-12-21 | 2022-06-30 | Advanced Accelerator Applications International Sa | Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5941386B2 (ja) | 1977-01-14 | 1984-10-06 | 株式会社紀文 | 高蛋白水産練製品様食品の製法 |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
DE69736812T2 (de) | 1996-11-27 | 2007-08-09 | Bristol-Myers Squibb Pharma Co. | Neue integrin rezeptor antagonisten |
BR9813769A (pt) * | 1997-12-17 | 2000-10-10 | Merck & Co Inc | Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste. |
US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
DE69936148T2 (de) * | 1998-12-18 | 2008-01-24 | Bristol-Myers Squibb Pharma Co. | Vitronektinrezeptorantagonist-arzneimittel |
US6511648B2 (en) * | 1998-12-18 | 2003-01-28 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
JP2003520271A (ja) | 2000-01-24 | 2003-07-02 | メルク エンド カムパニー インコーポレーテッド | αvインテグリン受容体拮抗薬 |
AU2001270025B2 (en) * | 2000-06-21 | 2005-08-18 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
JP4615826B2 (ja) | 2001-01-29 | 2011-01-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用 |
KR101383655B1 (ko) | 2010-05-24 | 2014-04-10 | 주식회사 바이오이미징코리아 | 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 |
FR2968999B1 (fr) * | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
FR2980364B1 (fr) * | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
WO2013048996A1 (en) | 2011-09-30 | 2013-04-04 | Ge Healthcare Limited | Method for the purification of a peptide-based imaging agent precursor |
PT2840080T (pt) * | 2012-04-17 | 2018-02-06 | Fujifilm Corp | Composto heterocíclico que contém azoto ou sal do mesmo |
FR3001154B1 (fr) * | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
JP6215335B2 (ja) * | 2013-09-24 | 2017-10-18 | 富士フイルム株式会社 | 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体 |
-
2016
- 2016-03-25 WO PCT/JP2016/059729 patent/WO2016153054A1/ja active Application Filing
- 2016-03-25 RU RU2017133107A patent/RU2720989C2/ru active
- 2016-03-25 CN CN201680018240.1A patent/CN107428755B/zh active Active
- 2016-03-25 BR BR112017020484-3A patent/BR112017020484B1/pt active IP Right Grant
- 2016-03-25 SG SG11201707899SA patent/SG11201707899SA/en unknown
- 2016-03-25 SG SG10201902609TA patent/SG10201902609TA/en unknown
- 2016-03-25 ES ES16768957T patent/ES2877707T3/es active Active
- 2016-03-25 EP EP22170836.5A patent/EP4059936A1/en active Pending
- 2016-03-25 LT LTEPPCT/JP2016/059729T patent/LT3275883T/lt unknown
- 2016-03-25 RU RU2020115068A patent/RU2767398C2/ru active
- 2016-03-25 PT PT167689579T patent/PT3275883T/pt unknown
- 2016-03-25 RS RS20210779A patent/RS62165B1/sr unknown
- 2016-03-25 DK DK16768957.9T patent/DK3275883T3/da active
- 2016-03-25 SI SI201631232T patent/SI3275883T1/sl unknown
- 2016-03-25 AU AU2016237099A patent/AU2016237099C1/en active Active
- 2016-03-25 JP JP2017508476A patent/JP6411634B2/ja active Active
- 2016-03-25 KR KR1020177026236A patent/KR102029746B1/ko active IP Right Grant
- 2016-03-25 CA CA2980268A patent/CA2980268C/en active Active
- 2016-03-25 EP EP16768957.9A patent/EP3275883B1/en active Active
- 2016-03-25 HU HUE16768957A patent/HUE059670T2/hu unknown
- 2016-03-25 EP EP21168086.3A patent/EP3872079A1/en not_active Withdrawn
- 2016-03-25 CN CN202010084360.XA patent/CN111171026B/zh active Active
- 2016-03-25 PL PL16768957T patent/PL3275883T3/pl unknown
- 2016-03-25 MX MX2017012184A patent/MX2017012184A/es unknown
-
2017
- 2017-09-17 IL IL254532A patent/IL254532B/en unknown
- 2017-09-22 US US15/712,815 patent/US20180008583A1/en not_active Abandoned
- 2017-09-25 MX MX2023005703A patent/MX2023005703A/es unknown
- 2017-09-25 MX MX2023005704A patent/MX2023005704A/es unknown
- 2017-10-24 CO CONC2017/0010806A patent/CO2017010806A2/es unknown
-
2019
- 2019-10-10 AU AU2019246859A patent/AU2019246859B2/en active Active
-
2020
- 2020-09-29 US US17/037,103 patent/US20210015802A1/en not_active Abandoned
- 2020-10-02 AU AU2020244578A patent/AU2020244578B2/en active Active
- 2020-10-02 AU AU2020244580A patent/AU2020244580B2/en active Active
-
2021
- 2021-05-18 IL IL283224A patent/IL283224B/en unknown
- 2021-05-19 IL IL283289A patent/IL283289B/en unknown
- 2021-05-19 IL IL283288A patent/IL283288B/en unknown
- 2021-06-29 HR HRP20211031TT patent/HRP20211031T1/hr unknown
- 2021-07-02 CY CY20211100591T patent/CY1124387T1/el unknown
-
2023
- 2023-02-21 US US18/112,423 patent/US20240108607A1/en active Pending